Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: SUMMARY: This review examines the history and provides a perspective regarding the extended-release niacin/ laropiprant development program, which was designed to better allow patients to achieve a more therapeutic niacin dose of 2 g/day, without the need for titration. Ongoing coronary heart disease outcome studies will provide better insight as to the benefits of niacin in general, and the safety and efficacy of extended-release niacin/ laropiprant specifically.
|
Authors | Harold E Bays, Christie Ballantyne |
Journal | Current opinion in lipidology
(Curr Opin Lipidol)
Vol. 20
Issue 6
Pg. 467-76
(Dec 2009)
ISSN: 1473-6535 [Electronic] England |
PMID | 19779335
(Publication Type: Journal Article, Review)
|
Chemical References |
- Delayed-Action Preparations
- Drug Combinations
- Hypolipidemic Agents
- Indoles
- Lipids
- MK-0524
- Niacin
|
Topics |
- Coronary Disease
(blood, drug therapy)
- Delayed-Action Preparations
- Drug Combinations
- Flushing
(chemically induced, prevention & control)
- Humans
- Hypolipidemic Agents
(adverse effects, therapeutic use)
- Indoles
(therapeutic use)
- Lipids
(blood)
- Niacin
(adverse effects, therapeutic use)
- Treatment Outcome
|